Cancer-related fatigue
CRF ยท cancer-associated fatigue
Cancer-related fatigue (CRF) is a distressing, persistent sense of physical, emotional or cognitive tiredness not proportional to recent activity and not relieved by rest. It affects 70-100% of patients during active cancer treatment and persists in 30-40% of long-term survivors. UK NHS survivorship resources, Macmillan, ESMO, NCCN and selected NICE cancer guidance emphasise multimodal management: exercise (the single highest-evidence intervention), psychological support, sleep hygiene, treatment of contributing factors (anaemia, thyroid, depression) and judicious pharmacotherapy.
Definition and epidemiology
- NCCN definition: "a distressing, persistent, subjective sense of physical, emotional, and/or cognitive tiredness or exhaustion related to cancer or cancer treatment that is not proportional to recent activity and interferes with usual functioning."
- Prevalence: 70-100% during treatment; 30-40% in 1-5 year survivors; long-term persistence in subsets.
- Most common cancer-related symptom; under-reported.
- Quality-of-life impact significant; affects function, sleep, mood, relationships, work.
Contributing factors
- Treatment-related:
- Chemotherapy.
- Radiotherapy.
- Immunotherapy (ICI).
- BRAF / MEK inhibitors.
- Targeted therapies.
- Surgery (especially major reconstruction).
- Tumour-related:
- Pro-inflammatory cytokine release (IL-6, TNF-ฮฑ, IL-1ฮฒ).
- Tumour burden, cachexia.
- Tumour-driven metabolic abnormalities.
- Concurrent factors:
- Anaemia (chemotherapy / chronic disease).
- Hypothyroidism (ICI-related, primary).
- Hypogonadism / adrenal insufficiency (especially after ICI).
- Electrolyte disturbance, dehydration.
- Pain.
- Sleep disturbance, insomnia.
- Depression, anxiety.
- Polypharmacy, particularly opioids, anticonvulsants, antihistamines.
- Deconditioning, inactivity.
Assessment
- NCCN screening: brief 0-10 NRS at each clinic visit ("Rate your fatigue in the past 7 days").
- โฅ4 โ comprehensive evaluation.
- Tools: FACIT-Fatigue, Brief Fatigue Inventory (BFI), MFI-20, Cancer Fatigue Scale.
- Investigations for treatable contributors:
- FBC, ferritin, B12, folate.
- U&E, calcium, magnesium.
- TFT, cortisol, testosterone, free T4 (low threshold post-ICI).
- Vitamin D, glucose / HbA1c.
- LFT.
- Sleep history, mood screen (HADS, PHQ-9).
Management
- Treat contributing factors: anaemia (iron / EPO if indicated), hypothyroidism, hypogonadism, depression, sleep, pain.
- Non-pharmacological (highest evidence):
- Exercise: 150 min / week moderate aerobic + 2ร weekly resistance. Strong evidence in Cochrane review.
- Tailored physiotherapy / cancer rehabilitation programme.
- Cognitive behavioural therapy (CBT) for cancer fatigue.
- Mindfulness-based stress reduction.
- Energy conservation techniques.
- Sleep hygiene.
- Yoga, tai chi.
- Pharmacological (limited evidence; selected cases):
- Methylphenidate 5-30 mg / day โ modest benefit in advanced disease.
- Modafinil โ limited evidence; not NICE-recommended for CRF.
- Antidepressants for concurrent depression.
- Corticosteroids (short-term) in end-of-life setting.
- Survivorship: integrated rehabilitation programme; Macmillan resources; cancer-specific gym schemes.
- Counsel: CRF is real and treatable; many patients fear it as "cancer return" โ reassurance plus active management.
References
- Mustian KM et al. Comparison of pharmaceutical, psychological, and exercise treatments for cancer-related fatigue: a meta-analysis. JAMA Oncol. 2017;3:961-968.
- Bower JE. Cancer-related fatigue: mechanisms, risk factors, and treatments. Nat Rev Clin Oncol. 2014;11:597-609.
- NCCN Clinical Practice Guidelines in Oncology. Cancer-related fatigue. Version 2.2024.
- NICE CG81. Advanced breast cancer: diagnosis and treatment. London: NICE; 2009 (last updated 19 February 2025). Section 1.5 includes cancer-related fatigue assessment and exercise advice.
- Cramp F, Byron-Daniel J. Exercise for the management of cancer-related fatigue in adults. Cochrane Database Syst Rev. 2012;11:CD006145.
- Macmillan Cancer Support. Coping with fatigue. London: Macmillan; 2024.
Spot a correction?
If any clinical statement, citation or link on this page needs updating, please email admin@skinoncology.net with the page name, the proposed correction and the supporting source.

